Protein & Antibody Engineering Summit (PEGS) Europe and Antibody Engineering & Therapeutics (AET) – November/December 2021

Engineering cis-targeted immunomodulators to enhance their selectivity and effectiveness as therapeutics
Andy Yeung, PhD

Society for Immunotherapy of Cancer (SITC) – November 2021

CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Hussein Sultan, PhD, Kelly Moynihan, PhD, Yuang Song, Ton Schumacher, PhD, Andy Yeung, PhD, Ivana Djuretic, PhD, and Robert D. Schreiber, PhD

Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety
Kelly Moynihan, PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Mike Chin, Ton Schumacher, PhD, Andy Yeung, PhD, and Ivana Djuretic, PhD


This links to an external website.